AGT Newsletter Volume 8
Featured Stories AGT’s HIV cure program is nearing a major milestone: Investigational New Drug (IND) submission. The IND is the key document that reports the safety data the FDA requires prior to a human trial...
AGT Newsletter Volume 7
Newsletter Vol. 7 In wrapping up the year, AGT was proud to be featured as a State of Maryland “Success Story” for its growth in Maryland and achievements in the gene and cell therapy industry. Watch The Vid...
AGT Newsletter Volume 6
NEWSLETTER VOL. 6 AGT’s progress over the first half of 2018 has been tremendous: six patents granted, major advances in all of its key projects: HIV, PKU and immuno-oncology, substantial momentum on socia...
AGT Newsletter Volume 5
End of year wrap-up Q4, 2017 Newsletter AGT is in position for key milestones and success in 2018. 2017 brought attention to the industry and particularly to AGT. We raised nearly $8M (approximately double the p...
